Screening and Characterization of Purine Nucleoside Degrading Lactic Acid Bacteria Isolated from Chinese Sauerkraut and Evaluation of the Serum Uric Acid Lowering Effect in Hyperuricemic Rats

Abstract

Hyperuricemia is well known as the cause of gout. In recent years, it has also been recognized as a risk factor for arteriosclerosis, cerebrovascular and cardiovascular diseases, and nephropathy in diabetic patients. Foods high in purine compounds are more potent in exacerbating hyperuricemia. Therefore, the development of probiotics that efficiently degrade purine compounds is a promising potential therapy for the prevention of hyperuricemia. In this study, fifty-five lactic acid bacteria isolated from Chinese sauerkraut were evaluated for the ability to degrade inosine and guanosine, the two key intermediates in purine metabolism. After a preliminary screening based on HPLC, three candidate strains with the highest nucleoside degrading rates were selected for further characterization. The tested biological characteristics of candidate strains included acid tolerance, bile tolerance, anti-pathogenic bacteria activity, cell adhesion ability, resistance to antibiotics and the ability to produce hydrogen peroxide. Among the selected strains, DM9218 showed the best probiotic potential compared with other strains despite its poor bile resistance. Analysis of 16S rRNA sequences showed that DM9218 has the highest similarity (99%) to Lactobacillus plantarum WCFS1. The acclimated strain DM9218-A showed better resistance to 0.3% bile salt, and its survival in gastrointestinal tract of rats was proven by PCR-DGGE. Furthermore, the effects of DM9218-A in a hyperuricemia rat model were evaluated. The level of serum uric acid in hyperuricemic rat can be efficiently reduced by the intragastric administration of DM9218-A (P<0.05). The preventive treatment of DM9218-A caused a greater reduction in serum uric acid concentration in hyperuricemic rats than the later treatment (P<0.05). Our results suggest that DM9218-A may be a promising candidate as an adjunctive treatment in patients with hyperuricemia during the onset period of disease. DM9218-A also has potential as a probiotic in the prevention of hyperuricemia in the normal population.

Dose-Dependent Effects of Multispecies Probiotic Supplementation on the Lipopolysaccharide (LPS) Level and Cardiometabolic Profile in Obese Postmenopausal Women: A 12-Week Randomized Clinical Trial

“…Li et al showed the efficacy of the preventive treatment of hyperuricemic rats with probiotic strain DM9218-A. These results suggest that DM9218-A may be a promising candidate for the treatment of patients with hyperuricemia in conjunction with other therapies [ 46 ]. DM9218-A may also be effective in the prevention of hyperuricemia in the normal population.…”

Co-Administration of Cholesterol-Lowering Probiotics and Anthraquinone from Cassia obtusifolia L. Ameliorate Non-Alcoholic Fatty Liver

“…The lactic bacteria (LAB) strains isolated from fermented food or healthy human intestine were screened by MRS-cholesterol broth with the Ammonium ferric sulfate method [ 18 ]. The properties of selected candidate strains, including tolerance to acid, bile, pepsin and trypsin, cell adhesion ability were evaluated [ 19 ]. They were identified by 16S rDNA sequencing and the sequences were submitted to NCBI under the GenBank Accession No.…”

Can Probiotics and Diet Promote Beneficial Immune Modulation and Purine Control in Coronavirus Infection?

“…L. fermentum ONRIC b0185, L. fermentum ONRIC b0195 e L. pentosus ONRIC b0223, presented in cell, culture high nucleosidase activity converting nucleoside into purine bases [ 54 ]. The Lactobacillus DM9218 strain also acts on the purine nucleosides (inosine and guanosine) [ 55 , 56 ]. L. gasseri PA3 has demonstrated an ability to reduce purine in foods and beverages [ 57 , 58 , 61 ].…”

“…Probiotics can help maintain or restore the balance of the intestinal microbiome and, consequently, improve the immune system’s response against aggression to the human organism [ 50 ]. Among the mechanisms of probiotics that corroborate with intestinal and systemic health is the competition with pathogenic microorganisms for adhesion sites and nutritional sources, the secretion of antimicrobial peptides, the action of metabolites, nucleosidase activity, and even immunomodulation by signaling pathways of intestinal and immune cells [ 51 , 52 , 53 , 54 , 55 , 56 ].…”

“…Besides the mechanisms well explored for probiotic action [ 51 , 52 , 53 , 54 , 55 , 56 ], a metabolic pathway has recently aroused the interest of researchers. This route involves the intestinal purine metabolism, possibly one of the explanations for the benefits achieved with the use of probiotics [ 57 , 58 ], to improve the immune system in cases of viral infections.…”